Effects of the encapsulation of usnic acid into liposomes and interactions with antituberculous agents against multidrug-resistant tuberculosis clinical isolates
Título del documento: Effects of the encapsulation of usnic acid into liposomes and interactions with antituberculous agents against multidrug-resistant tuberculosis clinical isolates
Revista: Memorias do Instituto Oswaldo Cruz
Base de datos: PERIÓDICA
Número de sistema: 000400769
ISSN: 0074-0276
Autors: 1
1
2
1
1
1
2
Institucions: 1Universidade Federal de Pernambuco, Laboratorio de Imunopatologia Keizo Asami, Recife, Pernambuco. Brasil
2Fundacao Oswaldo Cruz, Centro de Pesquisas Aggeu Magalhaes, Recife, Pernambuco. Brasil
Any:
Període: May
Volum: 111
Número: 5
Paginació: 330-334
País: Brasil
Idioma: Inglés
Tipo de documento: Artículo
Enfoque: Experimental, aplicado
Resumen en inglés Mycobacterium tuberculosis (Mtb) has acquired resistance and consequently the antibiotic therapeutic options available against this microorganism are limited. In this scenario, the use of usnic acid (UA), a natural compound, encapsulated into liposomes is proposed as a new approach in multidrug-resistant tuberculosis (MDR-TB) therapy. Thus the aim of this study was to evaluate the effect of the encapsulation of UA into liposomes, as well as its combination with antituberculous agents such as rifampicin (RIF) and isoniazid (INH) against MDR-TB clinical isolates. The in vitro antimycobacterial activity of UA-loaded liposomes (UA-Lipo) against MDR-TB was assessed by the microdilution method. The in vitro interaction of UA with antituberculous agents was carried out using checkerboard method. Minimal inhibitory concentration values were 31.25 and 0.98 µg/mL for UA and UA-Lipo, respectively. The results exhibited a synergistic interaction between RIF and UA [fractional inhibitory concentration index (FICI) = 0.31] or UA-Lipo (FICI = 0.28). Regarding INH, the combination of UA or UA-Lipo revealed no marked effect (FICI = 1.30-2.50). The UA-Lipo may be used as a dosage form to improve the antimycobacterial activity of RIF, a first-line drug for the treatment of infections caused by Mtb
Disciplines Medicina
Paraules clau: Farmacología,
Microbiología,
Tuberculosis,
Resistencia a fármacos,
Acido úsnico,
Liposomas,
Sinergismo,
Actividad antimicobacteriana,
Mycobacterium tuberculosis
Keyword: Medicine,
Microbiology,
Pharmacology,
Tuberculosis,
Drug resistance,
Usnic acid,
Liposomes,
Synergism,
Antimycobacterial activity,
Mycobacterium tuberculosis
Text complet: Texto completo (Ver HTML)